Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review - Report - MDSpire

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

  • By

  • Muratbek A. Tleubergenov

  • Altynay Bakbayeva

  • Daniyar K. Zhamoldin

  • Aidos Doskaliyev

  • Ulday M. Urazova

  • Aigul D. Tolepbergenova

  • Aisa Z. Nurpeisov

  • Zhanat T. Takenov

  • Serik Akshulakov

  • May 28, 2026

  • 0 min

Share

Clinical Report: IDH1-Mutant Astrocytoma WHO Grade 4 Diagnosed in Pregnancy

Overview

This report details a rare case of a 31-year-old pregnant woman diagnosed with an IDH1-mutant astrocytoma, WHO Grade 4, at 24 weeks of gestation. Despite surgical intervention, the tumor exhibited aggressive behavior, leading to rapid recurrence and ultimately the patient's death within two years.

Background

High-grade gliomas during pregnancy are rare and present unique clinical challenges. The molecular characteristics of these tumors, particularly IDH mutations and CDKN2A/B deletions, are critical for diagnosis and prognosis. Understanding the implications of these features is essential for managing both maternal and fetal health in such complex cases.

Data Highlights

No numerical data or trial data provided in the article.

Key Findings

  • The patient was diagnosed with an IDH1-mutant astrocytoma, WHO Grade 4, during the second trimester of pregnancy.
  • She exhibited a heterozygous CDKN2A/B deletion, which is associated with a poor prognosis.
  • Despite emergency craniotomy and subtotal tumor resection, the tumor recurred rapidly within five weeks.
  • A simultaneous cesarean section and re-craniotomy were performed at 31 weeks of gestation, with both mother and infant surviving the perioperative period.
  • The patient passed away within two years of diagnosis, underscoring the aggressive nature of the tumor.

Clinical Implications

This case highlights the importance of multidisciplinary care in managing high-grade gliomas during pregnancy. Clinicians should be aware of the potential for rapid tumor progression and the need for timely interventions. There is a critical need for clinical guidelines to address the management of such cases effectively.

Conclusion

The aggressive nature of IDH1-mutant astrocytomas with CDKN2A/B deletions necessitates careful monitoring and intervention strategies during pregnancy. Further research is needed to establish standardized management protocols for high-grade gliomas in pregnant patients.

Related Resources & Content

  1. Journal of Neuro-Oncology, 2018 -- Obstetric Considerations in Glioma Patients: A Comprehensive Review
  2. Journal of Neuro-Oncology, 2025 -- Comparing CDKN2A/B Deletion and Morphological Features in the Diagnosis of WHO Grade 4 IDH-Mutated Astrocytomas: Implications for Clinical Practice
  3. Acta Neuropathologica, 2025 -- Distinct Methylation Patterns and Increased Leptomeningeal Spread Risk in IDH-Mutant Astrocytomas Featuring Primitive Neuronal Components
  4. Journal of Neuro-Oncology, 2024 -- Factors Influencing Long-Term Outcomes in Patients with IDH-Mutated Gliomas
  5. Astrocytoma, IDH-mutant, grade 4 (Concept Id: C5238471) - MedGen - NCBI
  6. Management of Cancer During Pregnancy: ASCO Guideline | Journal of Clinical Oncology
  7. Astrocytoma, IDH-mutant, grade 4 (Concept Id: C5238471) - MedGen - NCBI
  8. Management of Cancer During Pregnancy: ASCO Guideline | Journal of Clinical Oncology

Original Source(s)

Related Content